EUCTR2006-004856-19-IT进行中（未招募）不适用
PEGYLATED LIPOSOMAL DOXORUBICIN (CAELYX), CISPLATINUM AND FLUOROURACIL AS CONTINUOUS INFUSION (CCF) IN LOCALLYADVANCED BREAST CANCER - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •? Patients with histologically proven locally advanced primary breast cancer (cT2-T3-T4 ad,
- •N0-3c, M0)or
- •Patients with histologically proven local recurrence after breast conserving surgery (rT1-
- •T4, N0-3c, M0) or
- •Patients with histologically proven local recurrence after mastectomy (M1 on the chest
- •Patients with histological proven regional recurrence (axillary, suvraclavicular and internal
- •mammary chain lymph nodes)
- •? Patients must be suitable for local treatment (radiotherapy and/or surgery) in a
- •multidisciplinary program
- •? Bilateral breast cancers are eligible
- •? Women aged 18?75 years
- •? ER PgR and c-erbB-2 expression defined according to EIO guidelines
- •? Performance status 0-2 (ECOG scale)
- •? Measurable and/or evaluable lesions
- •? No evidence of distant metastatic disease
- •? No clinically significant concomitant illness such as diabetes, cardiovascular, renal, or
- •neurological impairments
- •? LVEF >= 55% at basal echocardiography
- •? Absence of psychiatric illness undermining a correct understanding of the treatment
- •? WBC > 3,000/mm3; PLTS > 100,000/mm3
- •? AST, ALT, gamma-GT < 2.5 x upper normal limit and bilirubin < 1.5 mg/dl
- •? Serum creatinine in the normal range
- •? Institutional Signed Written Informed Consent obtained
- •? Pregnancy test (in fertile women). An effective contraceptive method must be prescribed
- •and its use verified for all women at potential risk of pregnancy
- •? Patients could have received prior anthracycline-including chemotherapy regimen for
- •breast cancer with a cumulative dose of doxorubicin<= 350 mg/m2 or epirubicin <= 720 mg/m2.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Presence of HER2/neu overexpression or amplification of Her2/neu gene
- •? Patients with other non-malignant uncontrolled systemic diseases that would
- •preclude trial entry in the opinion of the investigator. Specifically not eligible are
- •patients with uncontrolled active infection, chronic infection such as active HBV or
- •? Patients with distant metastatic disease
- •? Clinical grade greater than or equal to 2 peripheral neuropathy.
- •? Previous adjuvant and/or neoadjuvant treatment with anthracyclines, cisplatin and/or
- •5-FU ended less than 12 months before study entry
研究者
相似试验
进行中（未招募）
不适用
PEGYLATED LIPOSOMAL DOXORUBICIN (CAELYX), CISPLATINUMAND FLUOROURACIL AS CONTINUOUS INFUSION (CCF) PLUSTRASTUZUMAB (HERCEPTIN) IN THE PREOPERATIVE TREATMENT OFLOCALLY ADVANCED BREAST CANCER - NDlocally advanced breast cancerMedDRA version: 6.1Level: PTClassification code 10057654EUCTR2006-006010-15-ITISTITUTO EUROPEO DI ONCOLOGIA
进行中（未招募）
1 期
RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL (REPRAB study – MITO 36)MedDRA version: 22.0Level: LLTClassification code 10026311Term: Malignant neoplasm of ovary and other uterine adnexaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061535Term: Ovarian neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061344Term: Peritoneal neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian cancerEUCTR2017-004690-14-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE64
进行中（未招募）
不适用
Pegylated Liposomal Doxorubicin (Caleyx) in combination with Herceptin and Taxotere as first-line chemotherapy in metastatic breast cancer patients: A 2 stage Phase II, open label, Multicenter study.EUCTR2004-003989-15-ITSCHERING-PLOUGH
进行中（未招募）
不适用
ON PEGILATED LIPOSOMIAL DOXORUBICIN (TLC D-99) IN ASSOCIATION WITH IFOSFAMIDE IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA - NDMETASTATIC SOFT TISSUE SARCOMASMedDRA version: 9.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasEUCTR2008-003316-36-ITCENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO
进行中（未招募）
不适用
A phase II study of Pegylated Liposomal Doxorubicin PLD as preoperative treatment for elderly patients with locally advanced primary breast cancer. - NDocally advanced breast cancerMedDRA version: 6.1Level: PTClassification code 10057654EUCTR2005-005039-86-ITISTITUTO EUROPEO DI ONCOLOGIA30